New approaches to the treatment of congenital adrenal hyperplasia

JAMA

Volumn 277, Issue 13, 1997, Pages 1073-1076

  Merke, Deborah P ^a   Cutler, Gordon B ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUDROCORTISONE ACETATE; FLUTAMIDE; HYDROCORTISONE;

ARTICLE; CASE REPORT; CONGENITAL ADRENAL HYPERPLASIA; DRUG EFFICACY; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHOOL CHILD; STEROID THERAPY; TREATMENT PLANNING;

EID: 0030938764     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.13.1073     Document Type: Article

References (20)

1. Sane K, Pescovitz OH. The clitoral index: a determination of clitoral size in normal girls and in girls with abnormal sexual development. J Pediatr. 1992;120:264-266.
2. Callegari C, Everett S, Ross M, Brasel J. Anogenital ratio: measure of fetal virilization in premature and full-term newborn infants. J Pediatr. 1987;111:240-243.
3. Bristow J, Gitelman SE, Tee MK, Staels B, Miller WL. Abundant adrenal-specific transcription of the human P450c21A 'pseudogene.' J Biol Chem. 1993; 268:1219-1224.
4. Amor M, Parker KL, Globerman H, New MI, White PC. A mutation in the CYP21 gene (Ile-172 to Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci U S A. 1988;85:1600-1604.
5. Morel Y, André J, Uring-Lambert B, et al. Rearrangements and point mutations of P450c21 genes are distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia. J Clin Invest. 1989;83:527-536.
6. Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992;90:584-595.
7. Cutler GB Jr, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 1990;323:1806-1813.
8. Knorr D, Hinrichsen de Lienau SG. Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy. Acta Paediatr Jpn. 1988;30(suppl):89-92.
9. New MI, Gertner JM, Speiser PW, del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn. 1988; 30(suppl):79-88.
10. David M, Sempe M, Blanc M, Nicolino M, Forest MG, Morel Y. Taille définitive chez 69 sujets atteints d'hyperplasie congénitale des surrénales par déficit en 21-hydroxylase. Arch Pediatr. 1994; 1:363-367.
11. Shenker A, Laue L, Kosugi S, Merendino JJ, Minegishi T, Cutler GB. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 1993;365: 652-654.
12. Laue L, Kenigsberg D,-Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320:496-502.
13. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331: 1056-1061.
14. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689-3698.
15. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1996;81:3535-3539.
16. Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr. 1990; 117:892-896.
17. Girard J, Baumann JB. Corticotropin-releasing hormone-adrenocorticotropin suppression by an antiandrogenic drug (cyproterone acetate): a therapeutic possibility for congenital adrenal hyperplasia. In: Lee PA, Plotnick LP, Kowarski A, Migeon CJ, eds. Congenital Adrenal Hyperplasia. Baltimore, Md: University Park Press; 1977:217-230.
18. Wysowski DK, Friedman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118:860-864.
19. Gomez JL, Dupont A, Cusan L, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med. 1992;92: 465-470.
20. Van Wyk JJ, Gunther DF, Ritzen EM, et al. Therapeutic controversy: on the use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1996;81:3180-3190.